| abstract |
The present invention relates to a detection reagent for biomarkers for early diagnosis of pancreatic cancer, the biomarkers include blood extracellular vesicle miRNA biomarkers hsa-miR-95-3p and hsa-miR-26b-5p, and Further, it can be combined with the carbohydrate antigen CA19-9 in serum as a biomarker for distinguishing pancreatic cancer from pancreatitis. The present invention proposes and verifies the blood extracellular vesicle miRNA as a biomarker for the first time, and combines it with the expression level of the carbohydrate antigen CA19-9 in serum to distinguish pancreatitis and pancreatic cancer patients with high specificity, high sensitivity and high The positive predictive value is of great significance for the early diagnosis of pancreatic cancer. |